Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Entera BioSTU:5DT 26 Debt-to-EBITDA is -0.02 as of Jun. 2026. GuruFocus rates STU:5DT with a GF Score™ of 26/100 and a GF Value™ of €0.21 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 306 Biotechnology companies, Entera Bio ranks worse than 326797.06% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Entera Bio's Debt-to-EBITDA or its related term are showing as below:
STU:5DT'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.76 Med: -0.04 Max: -0.01
Current: -0.03
During the past 11 years, the highest Debt-to-EBITDA Ratio of Entera Bio was -0.01. The lowest was -2.76. And the median was -0.04.
STU:5DT's Debt-to-EBITDA is ranked worse than 100% of 306
companies
in the Biotechnology industry
Industry Median: 1.255
vs STU:5DT: -0.03
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Entera Bio Debt-to-EBITDA Related Terms
Entera Bio Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Entera Bio's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:5DT vs CABA, KYTX, SCTX: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Entera Bio's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entera Bio Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entera Bio's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Entera Bio's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Entera Bio (STU:5DT) has a Debt-to-EBITDA of -0.02 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Entera Bio. According to the industry distribution chart, Entera Bio ranks #999999 out of 306 companies in the Biotechnology industry.
Is Entera Bio's Debt-to-EBITDA too high?
Entera Bio's current Debt-to-EBITDA is -0.02. Based on the distribution chart, Entera Bio ranks #999999 out of 306 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Entera Bio has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Entera Bio's Debt-to-EBITDA compare to CABA and KYTX?
According to the Biotechnology industry distribution chart, Entera Bio ranks #999999 out of 306 companies for Debt-to-EBITDA. This places Entera Bio in the lower half of its industry. The industry median Debt-to-EBITDA is 1.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.26, based on 306 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Entera Bio. For the Biotechnology industry, the median Debt-to-EBITDA is 1.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entera Bio's current Debt-to-EBITDA is -0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entera Bio stock overvalued right now?
Based on GuruFocus' analysis, Entera Bio (STU:5DT) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.21, compared to a current price of €2.60 — trading 1138.1% above its estimated fair value. The current Debt-to-EBITDA is -0.02. Entera Bio's overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Entera Bio (STU:5DT), the current Debt-to-EBITDA is -0.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Entera Bio (STU:5DT) Overvalued in 2026?
Based on GuruFocus' analysis, Entera Bio stock appears to be overvalued.
The current stock price of €2.60 is trading 1138.1% above its estimated GF Value™ of €0.21.
GuruFocus considers Entera Bio to be Significantly Overvalued.
Key valuation signals for STU:5DT:
Debt-to-EBITDA: -0.02
GF Value™: €0.21 vs. price of €2.60 (1138.1% above fair value)
No single metric tells the full story. See the STU:5DT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
26GF Score
Get the complete analysis for STU:5DT
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:5DT has been successfully added to your 
